New study aims to protect kids from river blindness with safer dosing
NCT ID NCT03962062
First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 24 times
Summary
This study tested a single dose of moxidectin in 36 children aged 4 to 17 years who have or are at risk of onchocerciasis (river blindness). The goal was to find a dose for children 4 to 11 years that works as well as the 8 mg dose used in older people. Researchers measured drug levels in the blood and checked for side effects to ensure safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Health and Allied Services School of Public Health
Hohoe, Volta Region, Ghana
Conditions
Explore the condition pages connected to this study.